These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33842313)

  • 1. Management of
    Takeda H; Sunakawa Y
    Front Oncol; 2021; 11():602194. PubMed ID: 33842313
    [No Abstract]   [Full Text] [Related]  

  • 2. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR
    Elez E; Kopetz S; Tabernero J; Bekaii-Saab T; Taieb J; Yoshino T; Manji G; Fernandez K; Abbattista A; Zhang X; Morris VK
    Future Oncol; 2024 Apr; 20(11):653-663. PubMed ID: 37815847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
    Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
    Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Encorafenib plus cetuximab for the treatment of
    Ros J; Saoudi N; Baraibar I; Salva F; Tabernero J; Elez E
    Therap Adv Gastroenterol; 2022; 15():17562848221110644. PubMed ID: 35812780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
    Grothey A; Fakih M; Tabernero J
    Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Evolving Treatment Landscape in
    Tabernero J; Ros J; Élez E
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-10. PubMed ID: 35503983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Ros J; Baraibar I; Sardo E; Mulet N; Salvà F; Argilés G; Martini G; Ciardiello D; Cuadra JL; Tabernero J; Élez E
    Ther Adv Med Oncol; 2021; 13():1758835921992974. PubMed ID: 33747149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective Analysis of Treatment Pathways in Patients With BRAF
    Gerger A; Eisterer W; Fuxius S; Bastian S; Koeberle D; Welslau M; Sanoyan DA; Maas C; Uhlig J; Fenchel K; Greil R; VON DER Heyde E; Agocs GR; Weide R; Schwager M; Reichenbach F; Modest DP; Fritsch R
    Anticancer Res; 2022 Oct; 42(10):4773-4785. PubMed ID: 36191968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.
    Eriksen M; Pfeiffer P; Rohrberg KS; Yde CW; Petersen LN; Poulsen LØ; Qvortrup C
    BMC Cancer; 2022 Dec; 22(1):1321. PubMed ID: 36527039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Metastasectomy in the Multimodality Approach for
    Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A
    Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer.
    Lee HM; Morris V; Napolitano S; Kopetz S
    Oncology (Williston Park); 2019 Jun; 33(6):206-11. PubMed ID: 31219603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European expert panel consensus on the clinical management of BRAF
    Martinelli E; Arnold D; Cervantes A; Stintzing S; Van Cutsem E; Tabernero J; Taieb J; Wasan H; Ciardiello F
    Cancer Treat Rev; 2023 Apr; 115():102541. PubMed ID: 36931147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of Lynch syndrome, BRAF
    Zwart K; van der Baan FH; Cohen R; Aparicio T; de la Fouchardiére C; Lecomte T; Punt CJA; Sefrioui D; Verheijden RJ; Vink GR; Wensink GE; Zaanan A; Koopman M; Tougeron D; Roodhart JML
    Cancer Med; 2023 Aug; 12(15):15841-15853. PubMed ID: 37326121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version].
    Hummel M; Hegewisch-Becker S; Neumann J; Vogel A
    Pathologe; 2021 Nov; 42(6):578-590. PubMed ID: 33956173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.
    Shahjehan F; Kamatham S; Chandrasekharan C; Kasi PM
    Drugs Today (Barc); 2019 Nov; 55(11):683-693. PubMed ID: 31840683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
    Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B
    PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors.
    Xu T; Wang X; Wang Z; Deng T; Qi C; Liu D; Li Y; Ji C; Li J; Shen L
    Ther Adv Med Oncol; 2022; 14():17588359221105022. PubMed ID: 35747165
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Li ZN; Zhao L; Yu LF; Wei MJ
    Gastroenterol Rep (Oxf); 2020 Jun; 8(3):192-205. PubMed ID: 32665851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options.
    Hummel M; Hegewisch-Becker S; Neumann JHL; Vogel A
    Pathologe; 2021 Nov; 42(Suppl 1):98-109. PubMed ID: 34259881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.